Analyst Ratings for Allogene Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. The analysts have an average price target of $18.6 versus the current price of Allogene Therapeutics at $3.53, implying an upside. This current average has increased by 20.0% from the previous average price target of $15.50.
September 25, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts predict a significant upside for Allogene Therapeutics, with an average price target of $18.6, indicating a potential increase in the stock price.
The average price target given by analysts indicates a significant potential increase in the stock price of Allogene Therapeutics. This is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100